The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum.

DSpace/Manakin Repository

Search OPUS


Advanced Search

Browse

My Account

Show simple item record

dc.contributor.author Sarris, J
dc.contributor.author Kavanagh, DJ
dc.contributor.author Byrne, G
dc.contributor.author Bone, KM
dc.contributor.author Adams, J
dc.contributor.author Deed, G
dc.date.accessioned 2012-02-10T06:09:37Z
dc.date.issued 2009-08
dc.identifier.citation Psychopharmacology, 2009, 205 (3), pp. 399 - 407
dc.identifier.issn 0033-3158
dc.identifier.other C1UNSUBMIT en_US
dc.identifier.uri http://hdl.handle.net/10453/17077
dc.description.abstract RATIONALE: Piper methysticum (Kava) has been withdrawn in European, British, and Canadian markets due to concerns over hepatotoxic reactions. The WHO recently recommended research into "aqueous" extracts of Kava. OBJECTIVE: The objective of this study was to conduct the first documented human clinical trial assessing the anxiolytic and antidepressant efficacy of an aqueous extract of Kava. DESIGN AND PARTICIPANTS: The Kava Anxiety Depression Spectrum Study was a 3-week placebo-controlled, double-blind crossover trial that recruited 60 adult participants with 1 month or more of elevated generalized anxiety. Five Kava tablets per day were prescribed containing 250 mg of kavalactones/day. RESULTS: The aqueous extract of Kava reduced participants' Hamilton Anxiety Scale score in the first controlled phase by -9.9 (CI = 7.1, 12.7) vs. -0.8 (CI = -2.7, 4.3) for placebo and in the second controlled phase by -10.3 (CI = 5.8, 14.7) vs. +3.3 (CI = -6.8, 0.2). The pooled effect of Kava vs. placebo across phases was highly significant (p < 0.0001), with a substantial effect size (d = 2.24, eta(2)(p)). Pooled analyses also revealed highly significant relative reductions in Beck Anxiety Inventory and Montgomery-Asberg Depression Rating Scale scores. The aqueous extract was found to be safe, with no serious adverse effects and no clinical hepatotoxicity. CONCLUSIONS: The aqueous Kava preparation produced significant anxiolytic and antidepressant activity and raised no safety concerns at the dose and duration studied. Kava appears equally effective in cases where anxiety is accompanied by depression. This should encourage further study and consideration of globally reintroducing aqueous rootstock extracts of Kava for the management of anxiety.
dc.format Print-Electronic
dc.language eng
dc.relation.isbasedon 10.1007/s00213-009-1549-9
dc.title The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum.
dc.type Journal Article
dc.description.version Published
dc.parent Psychopharmacology
dc.journal.volume 3
dc.journal.volume 205
dc.journal.number 3 en_US
dc.publocation New York en_US
dc.identifier.startpage 399 en_US
dc.identifier.endpage 407 en_US
dc.cauo.name FOH.Faculty of Health en_US
dc.conference Verified OK en_US
dc.for 1117 Public Health and Health Services
dc.for 1110 Nursing
dc.personcode 112076
dc.percentage 50 en_US
dc.classification.name Public Health and Health Services en_US
dc.classification.type FOR-08 en_US
dc.edition en_US
dc.custom en_US
dc.date.activity en_US
dc.location.activity ISI:000268120400005 en_US
dc.description.keywords In-Vitro; Disorder; Metaanalysis; Efficacy; Benzodiazepines; Kavalactones; Inventory; Toxicity; Mood en_US
dc.description.keywords Science & Technology
dc.description.keywords Technology
dc.description.keywords Engineering, Civil
dc.description.keywords Engineering
dc.description.keywords ENGINEERING, CIVIL
dc.description.keywords thin-walled members
dc.description.keywords complementary energy
dc.description.keywords column-buckling
dc.description.keywords lateral torsional buckling
dc.description.keywords finite element
dc.description.keywords WARPING FUNCTION
dc.description.keywords I-BEAMS
dc.description.keywords STABILITY
dc.description.keywords ENERGY
dc.description.keywords Humans
dc.description.keywords Kava
dc.description.keywords Anti-Anxiety Agents
dc.description.keywords Antidepressive Agents
dc.description.keywords Plant Extracts
dc.description.keywords Phytotherapy
dc.description.keywords Cross-Over Studies
dc.description.keywords Double-Blind Method
dc.description.keywords Depression
dc.description.keywords Anxiety
dc.description.keywords Dose-Response Relationship, Drug
dc.description.keywords Adult
dc.description.keywords Middle Aged
dc.description.keywords Female
dc.description.keywords Male
dc.description.keywords Humans
dc.description.keywords Kava
dc.description.keywords Antidepressive Agents
dc.description.keywords Plant Extracts
dc.description.keywords Phytotherapy
dc.description.keywords Cross-Over Studies
dc.description.keywords Double-Blind Method
dc.description.keywords Anxiety
dc.description.keywords Depression
dc.description.keywords Dose-Response Relationship, Drug
dc.description.keywords Adult
dc.description.keywords Middle Aged
dc.description.keywords Female
dc.description.keywords Male
dc.description.keywords Anti-Anxiety Agents
dc.description.keywords Humans
dc.description.keywords Kava
dc.description.keywords Antidepressive Agents
dc.description.keywords Plant Extracts
dc.description.keywords Phytotherapy
dc.description.keywords Cross-Over Studies
dc.description.keywords Double-Blind Method
dc.description.keywords Anxiety
dc.description.keywords Depression
dc.description.keywords Dose-Response Relationship, Drug
dc.description.keywords Adult
dc.description.keywords Middle Aged
dc.description.keywords Female
dc.description.keywords Male
dc.description.keywords Anti-Anxiety Agents
pubs.embargo.period Not known
pubs.organisational-group /University of Technology Sydney
pubs.organisational-group /University of Technology Sydney/Faculty of Health
pubs.organisational-group /University of Technology Sydney/Strength - Health Services and Practice Research


Files in this item

This item appears in the following Collection(s)

Show simple item record